The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of nivolumab in patients treated by corticosteroid due to immune-related adverse events.
 
Ryoko Inaba Higashiyama
No Relationships to Disclose
 
Hidehito Horinouchi
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Novartis; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Genomic Health (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Katsutoshi Sekine
No Relationships to Disclose
 
Yuji Matsumoto
No Relationships to Disclose
 
Shuji Murakami
No Relationships to Disclose
 
Yasushi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan
Consulting or Advisory Role - Boehringer Ingelheim; GlaxoSmithKline; Lilly; Taiho Pharmaceutical
Research Funding - Abbvie; Lilly Japan; Pfizer
 
Shintaro Kanda
Honoraria - AstraZeneca; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst)
 
Yutaka Fujiwara
Speakers' Bureau - Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Eisai; OncoTherapy Science; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca; Ono Pharmaceutical